Bispecific Antibodies in the Treatment of Hematologic Malignancies

Monoclonal antibody therapies are an important approach for the treatment of hematologic malignancies, but typically show low single‐agent activity. Bispecific antibodies, however, redirect immune cells to the tumor for subsequent lysis, and preclinical and accruing clinical data support single‐agen...

Descripción completa

Detalles Bibliográficos
Autores principales: Duell, Johannes, Lammers, Philip E., Djuretic, Ivana, Chunyk, Allison G., Alekar, Shilpa, Jacobs, Ira, Gill, Saar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766786/
https://www.ncbi.nlm.nih.gov/pubmed/30770546
http://dx.doi.org/10.1002/cpt.1396

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766786/
https://www.ncbi.nlm.nih.gov/pubmed/30770546
http://dx.doi.org/10.1002/cpt.1396

Ejemplares similares